Study on the expression and meaning of FBXW7 and ENO1 in high and low grade serous ovarian adenocarcinoma tissue

Abstract

Objective To investigate the expression and significance of FBXW7 and ENO1 in ovarian serous adenocarcinoma of different grades. Methods Immunohistochemistry was used to study the expression of FBXW7 and ENO1 in 60 cases of ovarian serous adenocarcinoma.The relationship between FBXW7 and ENO1 proteins and the prognosis of ovarian serous adenocarcinoma was analyzed. Results The positive rate of FBXW7 expression was 22.5% (9/40) in 40 cases of ovarian high grade adenocarcinoma and 10 cases in 15 cases of normal oviduct.The positive rate of FBXW7 expression was 66.7% (10/15), and the difference was statistically significant (P=0.003). The expression of FBXW7 in 20 cases of low grade adenocarcinoma was 5 cases, and the positive rate was 25.0%(5/20). In 15 cases of normal ovarian tissue, 9 cases were positive, and the positive rate was 60.0%(9/15). The difference was statistically significant (P=0.04). The expression of ENO1 protein was 27 in 40 cases of high grade adenocarcinoma, and the positive rate of expression was 67.5%(27/40).5 cases were positive in 15 normal fallopian tubes, and the positive rate was 33.3%(5/15). The difference was statistically significant (P=0.024). The expression of ENO1 protein was 15 in 20 cases of low grade adenocarcinoma, and the positive rate of expression was 75.0%(15/20). In 15 cases of normal ovarian tissue, 4 cases were positive, and the positive rate was 26.7%(4/15). The difference was statistically significant (P=0.006). There was no correlation between the low expression of FBXW7 and the high expression of ENO1 in high grade ovarian adenocarcinoma (P=0.199), but there was a significant correlation between the low expression of FBXW7 and the high expression of ENO1 in low grade ovarian adenocarcinoma (P<0.05). In low grade serous adenocarcinoma, the 5-year survival rates were 44.4% and 32.1% respectively, with no significant difference (P=0.052). In ovarian high-grade serous adenocarcinoma, the 5-year survival rates of high-expression group and low-expression group were 20.0% and 7.7%, respectively, with no significant difference (P=0.097). In low grade ovarian serous adenocarcinoma, the 5-year survival rate was 7.4% in high expression group and 50.0% in low expression group (P=0.023). The 5-year survival rates of ENO1 in high-grade serous adenocarcinoma were 0% and 40.0% in high-expression group and low-expression group respectively (P=0.001). Conclusion The low expression of FBXW7 in ovarian adenocarcinoma suggests that FBXW7 may be a tumor suppressor gene in ovarian serous adenocarcinoma, and ENO1 may be an oncogene in ovarian adenocarcinoma.The high expression of FBXW7 in serous adenocarcinoma indicates that ENO1 may be an oncogene, and the survival rate of FBXW7 in serous adenocarcinoma is higher than that in low expression group.The survival rate of the high-expression group was lower than that of the low-expression group.Therefore, they may become a new diagnostic index and therapeutic target for ovarian serous adenocarcinoma. Key words: FBXW7; ENO1; Advanced ovarian serous carcinoma; Ovaroian low-level serous carcinoma; Immunohistochemistry method